clavulanic acid ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
beta-lactamase inhibitors 669 58001-44-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • clavulanic acid
  • clavulanate
  • clavulanate potassium
  • clavulante potasium
  • clavulanate potassium salt
A beta-lactam antibiotic produced by the actinobacterium Streptomyces clavuligerus. It is a suicide inhibitor of bacterial beta-lactamase enzymes. Administered alone, it has only weak antibacterial activity against most organisms, but given in combination with other beta-lactam antibiotics it prevents antibiotic inactivation by microbial lactamase.
  • Molecular weight: 199.16
  • Formula: C8H9NO5
  • CLOGP: -1.06
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 2
  • TPSA: 87.07
  • ALOGS: 0.23
  • ROTB: 2

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 43 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 31.38 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 75 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.22 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 3.10 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.91 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.90 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Aug. 6, 1984 FDA DR REDDYS LABS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Bronchiectasis 114.93 21.02 41 4584 11393 56276049
Bone erosion 104.16 21.02 41 4584 14933 56272509
Acute generalised exanthematous pustulosis 75.63 21.02 29 4596 9840 56277602
Hypothyroidism 72.87 21.02 43 4582 38153 56249289
Neutropenia 57.86 21.02 68 4557 158099 56129343
Anaphylactic reaction 55.87 21.02 43 4582 58952 56228490
Drug hypersensitivity 53.29 21.02 87 4538 275118 56012324
Nail dystrophy 48.49 21.02 12 4613 940 56286502
Axillary pain 41.42 21.02 12 4613 1713 56285729
Loss of personal independence in daily activities 40.17 21.02 41 4584 81328 56206114
Hepatitis cholestatic 39.16 21.02 16 4609 6398 56281044
Cholecystitis chronic 38.86 21.02 18 4607 9730 56277712
Appendicitis 37.10 21.02 16 4609 7316 56280126
Jaundice 35.19 21.02 24 4601 27270 56260172
Catheter site haemorrhage 34.82 21.02 12 4613 3006 56284436
Pruritus 33.96 21.02 78 4547 316545 55970897
Cholestasis 30.80 21.02 22 4603 26891 56260551
Toxic skin eruption 29.93 21.02 16 4609 11723 56275719
Hyperleukocytosis 28.65 21.02 7 4618 520 56286922
Red blood cell sedimentation rate abnormal 27.89 21.02 18 4607 18655 56268787
Clostridium difficile colitis 25.40 21.02 17 4608 18721 56268721
Dementia 24.30 21.02 16 4609 17142 56270300
Thrombotic microangiopathy 21.69 21.02 12 4613 9399 56278043

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hepatocellular injury 85.82 26.26 43 3312 21501 31672488
Spinal muscular atrophy 78.60 26.26 16 3339 395 31693594
Motor neurone disease 74.97 26.26 16 3339 500 31693489
Pneumococcal sepsis 74.78 26.26 18 3337 972 31693017
Stoma closure 66.66 26.26 13 3342 256 31693733
Ischaemic cerebral infarction 66.60 26.26 17 3338 1170 31692819
Lymphadenectomy 62.42 26.26 13 3342 360 31693629
Bronchial disorder 59.68 26.26 16 3339 1333 31692656
Lower respiratory tract infection bacterial 59.27 26.26 13 3342 463 31693526
Increased bronchial secretion 55.17 26.26 16 3339 1778 31692211
Urethral valves 54.01 26.26 11 3344 272 31693717
Cholestasis 52.97 26.26 33 3322 25042 31668947
Sputum increased 52.35 26.26 16 3339 2129 31691860
Disease complication 49.54 26.26 16 3339 2547 31691442
Scoliosis 49.32 26.26 16 3339 2583 31691406
Demyelination 47.31 26.26 16 3339 2939 31691050
Motor dysfunction 45.25 26.26 19 3336 6320 31687669
Resuscitation 45.24 26.26 13 3342 1398 31692591
Respiratory tract infection bacterial 44.75 26.26 13 3342 1453 31692536
Metabolic disorder 42.67 26.26 16 3339 3958 31690031
Chest X-ray abnormal 42.29 26.26 16 3339 4057 31689932
Brain injury 39.97 26.26 17 3338 5833 31688156
Circulatory collapse 39.21 26.26 25 3330 19719 31674270
Anaphylactic shock 38.68 26.26 22 3333 14123 31679866
Lung consolidation 37.71 26.26 16 3339 5457 31688532
Muscle atrophy 37.13 26.26 17 3338 6944 31687045
Intestinal ischaemia 36.94 26.26 17 3338 7028 31686961
Anaphylactic reaction 36.59 26.26 28 3327 29525 31664464
Stevens-Johnson syndrome 34.50 26.26 22 3333 17350 31676639
Hepatitis cholestatic 33.62 26.26 16 3339 7130 31686859
Mechanical ventilation 33.36 26.26 11 3344 1868 31692121
Cerebral ischaemia 33.21 26.26 15 3340 5940 31688049
Secretion discharge 32.58 26.26 14 3341 4923 31689066
Kounis syndrome 32.24 26.26 11 3344 2073 31691916
Meningitis aseptic 31.97 26.26 12 3343 2976 31691013
Endotracheal intubation 28.80 26.26 11 3344 2859 31691130

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anaphylactic reaction 89.22 19.86 67 6824 74907 70846646
Hepatocellular injury 87.61 19.86 55 6836 46036 70875517
Cholestasis 83.23 19.86 54 6837 47818 70873735
Spinal muscular atrophy 78.93 19.86 16 6875 422 70921131
Motor neurone disease 74.10 19.86 16 6875 577 70920976
Acute generalised exanthematous pustulosis 73.78 19.86 34 6857 15363 70906190
Pneumococcal sepsis 69.15 19.86 18 6873 1458 70920095
Stoma closure 67.01 19.86 13 6878 272 70921281
Meningitis aseptic 53.51 19.86 21 6870 6398 70915155
Lower respiratory tract infection bacterial 52.46 19.86 13 6878 864 70920689
Bronchial disorder 52.21 19.86 16 6875 2338 70919215
Ischaemic cerebral infarction 52.19 19.86 16 6875 2341 70919212
Bone erosion 50.14 19.86 26 6865 15147 70906406
Lymphadenectomy 48.80 19.86 13 6878 1151 70920402
Bronchiectasis 48.69 19.86 26 6865 16071 70905482
Hepatitis cholestatic 48.59 19.86 24 6867 12626 70908927
Increased bronchial secretion 47.92 19.86 16 6875 3077 70918476
Nail dystrophy 46.54 19.86 12 6879 936 70920617
Kounis syndrome 46.38 19.86 16 6875 3395 70918158
Jaundice 45.03 19.86 38 6853 50070 70871483
Respiratory tract infection bacterial 43.66 19.86 13 6878 1724 70919829
Sputum increased 43.61 19.86 16 6875 4056 70917497
Anaphylactic shock 43.03 19.86 31 6860 32459 70889094
Stevens-Johnson syndrome 42.47 19.86 32 6859 35875 70885678
Disease complication 42.00 19.86 16 6875 4501 70917052
Resuscitation 39.86 19.86 13 6878 2324 70919229
Axillary pain 38.20 19.86 12 6879 1903 70919650
Demyelination 37.88 19.86 17 6874 7219 70914334
Toxic epidermal necrolysis 37.62 19.86 31 6860 39526 70882027
Brain injury 37.41 19.86 19 6872 10598 70910955
Drug hypersensitivity 37.19 19.86 80 6811 262379 70659174
Clostridium difficile colitis 36.88 19.86 27 6864 28969 70892584
Scoliosis 36.34 19.86 16 6875 6495 70915058
Metabolic disorder 36.16 19.86 17 6874 8023 70913530
Chest X-ray abnormal 34.92 19.86 16 6875 7128 70914425
Pruritus 34.57 19.86 92 6799 345468 70576085
Drug reaction with eosinophilia and systemic symptoms 32.80 19.86 34 6857 57979 70863574
Lung consolidation 32.62 19.86 16 6875 8290 70913263
Intestinal ischaemia 32.36 19.86 18 6873 12046 70909507
Circulatory collapse 32.07 19.86 27 6864 35447 70886106
Muscle atrophy 32.06 19.86 17 6874 10353 70911200
Hypothyroidism 31.77 19.86 30 6861 45725 70875828
Mechanical ventilation 30.85 19.86 11 6880 2570 70918983
Tachypnoea 28.39 19.86 23 6868 28615 70892938
Motor dysfunction 28.39 19.86 17 6874 13053 70908500
Jaundice cholestatic 28.24 19.86 15 6876 9169 70912384
Catheter site haemorrhage 27.38 19.86 12 6879 4819 70916734
Neutropenia 27.25 19.86 70 6821 257086 70664467
Endotracheal intubation 25.29 19.86 11 6880 4335 70917218
Mixed liver injury 24.42 19.86 12 6879 6237 70915316
Bronchospasm 24.08 19.86 19 6872 22773 70898780
Cerebral ischaemia 23.81 19.86 14 6877 10398 70911155
Purpura 23.45 19.86 17 6874 17958 70903595
Liver injury 23.10 19.86 24 6867 41011 70880542
Aspartate aminotransferase increased 23.10 19.86 43 6848 126935 70794618
Appendicitis 22.23 19.86 16 6875 16717 70904836
Secretion discharge 21.02 19.86 14 6877 12919 70908634
Lung infiltration 20.66 19.86 17 6874 21607 70899946
Atelectasis 20.12 19.86 19 6872 28943 70892610
Hepatitis acute 20.05 19.86 14 6877 13948 70907605
Cholangitis 19.98 19.86 13 6878 11536 70910017
Injury 19.97 19.86 28 6863 65217 70856336

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
FDA MoA N0000000202 beta Lactamase Inhibitors
FDA EPC N0000175930 beta Lactamase Inhibitor
CHEBI has role CHEBI:35474 anti-anxiety agents
CHEBI has role CHEBI:35625 beta-lactamase inhibitors
CHEBI has role CHEBI:36047 antibacterial drugs
CHEBI has role CHEBI:33281 antibiotics
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents
MeSH PA D065093 beta-Lactamase Inhibitors
MeSH PA D004791 Enzyme Inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Septicemia due to Escherichia coli indication 9323009
Bacterial septicemia indication 10001005 DOID:0040085
Infection of skin AND/OR subcutaneous tissue indication 19824006
Staphylococcal pneumonia indication 22754005
Bacterial pneumonia indication 53084003 DOID:874
Klebsiella cystitis indication 60867007
Pneumonia due to Klebsiella pneumoniae indication 64479007
Urinary tract infectious disease indication 68566005
Haemophilus influenzae pneumonia indication 70036007
Infection due to Escherichia coli indication 71057007
Rhinoscleroma indication 72409005 DOID:11336
Acute bacterial sinusitis indication 75498004
Bacterial infection due to Klebsiella pneumoniae indication 186435004
Pneumococcal pneumonia indication 233607000
Escherichia coli urinary tract infection indication 301011002
Bacterial urinary infection indication 312124009
Infective otitis media indication 312218008
Infection due to Staphylococcus aureus indication 406602003
Osteomyelitis due to Staphylococcus aureus indication 428783003
Pneumonia due to Staphylococcus aureus indication 441658007
Sepsis due to Staphylococcus aureus indication 448417001
Sepsis due to Pseudomonas indication 448813005
Bacteroides Endometritis indication
Pneumococcal Acute Otitis Media indication
Haemophilus Parainfluenzae Pneumonia indication
Pseudomonas Aeruginosa Urinary Tract Infection indication
Klebsiella Endometritis indication
Klebsiella Pneumoniae Peritonitis indication
Haemophilus Influenzae Acute Otitis Media indication
Moraxella Catarrhalis Pneumonia indication
Moraxella Catarrhalis Acute Otitis Media indication
Staphylococcus Aureus Joint Infection indication
Staphylococcus Aureus Urinary Tract Infection indication
E. Coli Peritonitis indication
Enterobacter Endometritis indication
Bacteroides Peritonitis indication
Serratia Urinary Tract Infection indication
Citrobacter Urinary Tract Infection indication
Staphylococcus Endometritis indication
E. Coli Endometritis indication
Acute otitis media off-label use 3110003
Pyrexia of unknown origin off-label use 7520000
Chronic purulent otitis media off-label use 38394007 DOID:14247
Cholangitis off-label use 82403002 DOID:9446
Human bite - wound off-label use 262555007
Chancroid off-label use 266143009 DOID:13778
Diverticulitis of gastrointestinal tract off-label use 271366000
Dog bite - wound off-label use 283734005
Cat bite - wound off-label use 283782004
Acute exacerbation of chronic bronchitis off-label use 425748003
Pseudomonas Respiratory Tract Infection in Cystic Fibrosis off-label use
Diabetic Foot Infection off-label use
Obstruction of bile duct contraindication 30144000
Kidney disease contraindication 90708001 DOID:557
Disease of liver contraindication 235856003 DOID:409
Infectious mononucleosis contraindication 271558008 DOID:8568
Pseudomembranous enterocolitis contraindication 397683000




๐Ÿถ Veterinary Drug Use

SpeciesUseRelation
Dogs Urinary tract infections caused by Escherichia coli Indication
Dogs Skin and soft tissue infections caused by beta-lactamase producing Staphylococcus aureus Indication
Dogs Skin and soft tissue infections caused by Staphylococcus spp Indication
Dogs Skin and soft tissue infections caused by Streptococcus spp Indication
Dogs Skin and soft tissue infections caused by Escherichia coli Indication
Dogs Skin and soft tissue infections caused by Pasteurella spp Indication
Cats Urinary tract infections caused by Escherichia coli Indication
Cats Skin and soft tissue infections caused by beta-lactamase producing Staphylococcus aureus Indication
Cats Skin and soft tissue infections caused by Staphylococcus spp Indication
Cats Skin and soft tissue infections caused by Streptococcus spp Indication
Cats Skin and soft tissue infections caused by Escherichia coli Indication
Cats Skin and soft tissue infections caused by Pasteurella spp Indication
Cats Periodontal infections due aerobic and anaerobic bacteria Indication

๐Ÿถ Veterinary products

ProductApplicantIngredients
CLAVAMOX CHEWABLE Tablets, CLAVAMOX tablets Zoetis Inc. 2
Clavamox Drops Zoetis Inc. 2
Clavacillin Dechra Veterinary Products LLC 2
Amoxicillin and Clavulanate Potassium for Oral Suspension Dechra Veterinary Products LLC 2
Amoxicillin and Clavulanate Potassium Tablets Cronus Pharma Specialities India Private Limited 2
Amoxicillin and Clavulanate Potassium for Oral Suspension Cronus Pharma Specialities India Private Limited 2

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.07 acidic
pKa2 13.53 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Beta-lactamase TEM Enzyme INHIBITOR IC50 10.19 WOMBAT-PK CHEMBL
Beta-lactamase Enzyme IC50 7.82 CHEMBL
Beta-lactamase Enzyme IC50 4 CHEMBL
Beta-lactamase SHV-1 Enzyme IC50 7.55 CHEMBL
Beta-lactamase Enzyme Kd 6.40 CHEMBL
Beta-lactamase OXA-1 Enzyme IC50 5.49 CHEMBL
Beta-lactamase Enzyme IC50 6.10 CHEMBL
Beta-lactamase Enzyme IC50 8.05 CHEMBL
Beta-lactamase Enzyme IC50 7.15 CHEMBL
Beta-lactamase Enzyme IC50 7.07 CHEMBL
Carbapenem-hydrolizing beta-lactamase SFC-1 Enzyme IC50 4.14 CHEMBL
Carbepenem-hydrolyzing beta-lactamase KPC Enzyme Ki 4.96 CHEMBL
Beta-lactamase Enzyme IC50 7.17 CHEMBL
Beta-lactamase Enzyme IC50 8.05 CHEMBL
Beta-lactamase SHV-1 Enzyme IC50 6.77 CHEMBL
Beta-lactamase Enzyme IC50 5.07 CHEMBL
Beta-lactamase GES-13 Enzyme IC50 7 CHEMBL
Beta-lactamase Enzyme IC50 5.76 CHEMBL
Beta-lactamase Enzyme IC50 7.70 CHEMBL
Class D beta-lactamase Unclassified IC50 5.70 CHEMBL
Beta-lactamase Enzyme IC50 8 CHEMBL
Beta-lactamase SHV-5 Enzyme Ki 4.60 CHEMBL
Beta-lactamase Enzyme IC50 7 CHEMBL
Beta-lactamase Enzyme IC50 7 CHEMBL
Beta-lactamase Enzyme MPC 8.72 WOMBAT-PK
Beta-lactamase Enzyme IC50 7.44 CHEMBL

External reference:

IDSource
N0000005804 NUI
D02370 KEGG_DRUG
61177-45-5 SECONDARY_CAS_RN
21216 RXNORM
4018406 VANDF
4019680 VANDF
C0055860 UMLSCUI
CHEBI:48947 CHEBI
J01 PDB_CHEM_ID
CHEMBL777 ChEMBL_ID
DB00766 DRUGBANK_ID
CHEMBL1003 ChEMBL_ID
D019818 MESH_DESCRIPTOR_UI
5280980 PUBCHEM_CID
4948 INN_ID
11128 IUPHAR_LIGAND_ID
23521W1S24 UNII
4463 MMSL
d04405 MMSL
002808 NDDF
002809 NDDF
395938000 SNOMEDCT_US
395939008 SNOMEDCT_US
412318009 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Amoxicillin and Clavulanate Potassium HUMAN PRESCRIPTION DRUG LABEL 2 0093-2270 TABLET, CHEWABLE 28.50 mg ORAL ANDA 26 sections
Amoxicillin and Clavulanate Potassium HUMAN PRESCRIPTION DRUG LABEL 2 0093-2270 TABLET, CHEWABLE 28.50 mg ORAL ANDA 26 sections
Amoxicillin and Clavulanate Potassium HUMAN PRESCRIPTION DRUG LABEL 2 0093-2272 TABLET, CHEWABLE 57 mg ORAL ANDA 26 sections
Amoxicillin and Clavulanate Potassium HUMAN PRESCRIPTION DRUG LABEL 2 0093-2272 TABLET, CHEWABLE 57 mg ORAL ANDA 26 sections
Amoxicillin and Clavulanate Potassium HUMAN PRESCRIPTION DRUG LABEL 2 0093-2274 TABLET, FILM COATED 125 mg ORAL ANDA 26 sections
Amoxicillin and Clavulanate Potassium HUMAN PRESCRIPTION DRUG LABEL 2 0093-2274 TABLET, FILM COATED 125 mg ORAL ANDA 26 sections
Amoxicillin and Clavulanate Potassium HUMAN PRESCRIPTION DRUG LABEL 2 0093-2275 TABLET, FILM COATED 125 mg ORAL ANDA 26 sections
Amoxicillin and Clavulanate Potassium HUMAN PRESCRIPTION DRUG LABEL 2 0093-2275 TABLET, FILM COATED 125 mg ORAL ANDA 26 sections
Amoxicillin and Clavulanate Potassium HUMAN PRESCRIPTION DRUG LABEL 2 0093-2277 POWDER, FOR SUSPENSION 28.50 mg ORAL ANDA 26 sections
Amoxicillin and Clavulanate Potassium HUMAN PRESCRIPTION DRUG LABEL 2 0093-2277 POWDER, FOR SUSPENSION 28.50 mg ORAL ANDA 26 sections
Amoxicillin and Clavulanate Potassium HUMAN PRESCRIPTION DRUG LABEL 2 0093-2279 POWDER, FOR SUSPENSION 57 mg ORAL ANDA 26 sections
Amoxicillin and Clavulanate Potassium HUMAN PRESCRIPTION DRUG LABEL 2 0093-2279 POWDER, FOR SUSPENSION 57 mg ORAL ANDA 26 sections
Amoxicillin and Clavulanate Potassium HUMAN PRESCRIPTION DRUG LABEL 2 0093-8675 POWDER, FOR SUSPENSION 42.90 mg ORAL ANDA 26 sections
Amoxicillin and Clavulanate Potassium HUMAN PRESCRIPTION DRUG LABEL 2 0093-8675 POWDER, FOR SUSPENSION 42.90 mg ORAL ANDA 26 sections
Amoxicillin and Clavulanate Potassium HUMAN PRESCRIPTION DRUG LABEL 2 0143-9249 TABLET 125 mg ORAL ANDA 28 sections
Amoxicillin and Clavulanate Potassium HUMAN PRESCRIPTION DRUG LABEL 2 0143-9853 SUSPENSION 42.90 mg ORAL ANDA 32 sections
Amoxicillin and Clavulanate Potassium HUMAN PRESCRIPTION DRUG LABEL 2 0143-9853 SUSPENSION 42.90 mg ORAL ANDA 32 sections
Amoxicillin and Clavulanate Potassium HUMAN PRESCRIPTION DRUG LABEL 2 0143-9981 POWDER, FOR SUSPENSION 28.50 mg ORAL ANDA 30 sections
Amoxicillin and Clavulanate Potassium HUMAN PRESCRIPTION DRUG LABEL 2 0143-9981 POWDER, FOR SUSPENSION 28.50 mg ORAL ANDA 30 sections
Amoxicillin and Clavulanate Potassium HUMAN PRESCRIPTION DRUG LABEL 2 0143-9982 POWDER, FOR SUSPENSION 57 mg ORAL ANDA 30 sections
Amoxicillin and Clavulanate Potassium HUMAN PRESCRIPTION DRUG LABEL 2 0143-9982 POWDER, FOR SUSPENSION 57 mg ORAL ANDA 30 sections
Amoxicillin and Clavulanate Potassium HUMAN PRESCRIPTION DRUG LABEL 2 0781-1619 TABLET, CHEWABLE 28.50 mg ORAL ANDA 27 sections
Amoxicillin and Clavulanate Potassium HUMAN PRESCRIPTION DRUG LABEL 2 0781-1619 TABLET, CHEWABLE 28.50 mg ORAL ANDA 27 sections
Amoxicillin and Clavulanate Potassium HUMAN PRESCRIPTION DRUG LABEL 2 0781-1643 TABLET, CHEWABLE 57 mg ORAL ANDA 27 sections
Amoxicillin and Clavulanate Potassium HUMAN PRESCRIPTION DRUG LABEL 2 0781-1643 TABLET, CHEWABLE 57 mg ORAL ANDA 27 sections
Amoxicillin and Clavulanate Potassium HUMAN PRESCRIPTION DRUG LABEL 2 0781-1831 TABLET, FILM COATED 125 mg ORAL ANDA 27 sections
Amoxicillin and Clavulanate Potassium HUMAN PRESCRIPTION DRUG LABEL 2 0781-1831 TABLET, FILM COATED 125 mg ORAL ANDA 27 sections
Amoxicillin and Clavulanate Potassium HUMAN PRESCRIPTION DRUG LABEL 2 0781-1852 TABLET, FILM COATED 125 mg ORAL ANDA 27 sections
Amoxicillin and Clavulanate Potassium HUMAN PRESCRIPTION DRUG LABEL 2 0781-1852 TABLET, FILM COATED 125 mg ORAL ANDA 27 sections
Amoxicillin and Clavulanate Potassium HUMAN PRESCRIPTION DRUG LABEL 2 0781-1874 TABLET, FILM COATED 125 mg ORAL ANDA 27 sections